| Date |
Subject |
Media |
| 2025-07-01 |
Genomics BioSci & Tech. Targets Profitability and Launches IPO Plan for 2025
|
Genomics BioSci & Tech. (Genomics) held its annual shareholders’ meeting on the 20th, approving a cash capital increase through public offering in preparation for its initial public offering (IPO). Shareholders also agreed to waive their preemptive rights, officially initiating the company’s IPO process. Chairman Meng-Hsien Chou stated that following a strategic business realignment, the company is now focused on revenue growth and aims to achieve profitability this year. |
| 2025-07-01 |
The 2026 World Congress of Internal Medicine to Be Held in Taiwan: Ming-Shiang Wu Hopes to Showcase Taiwan's Medical Strength
|
In a major step toward elevating Taiwan’s global visibility in healthcare and realizing the vision of a “Healthy Taiwan,” the Taiwan Society of Internal Medicine has successfully secured the bid to host the 2026 World Congress of Internal Medicine. The Society announced that the event will bring together over 8,000 internists, scholars, and researchers from around the world to Taiwan. The congress will focus on the importance of preventive medicine in internal medicine, particularly the critical role of adult vaccination in enhancing public health. Through cross-sector collaboration and policy advocacy, the event aims to demonstrate Taiwan’s strong commitment to improving healthcare quality and extending healthy life expectancy. |
| 2025-07-01 |
Locus Cell Secures Another International Order, Partners with Japan’s CellFiber to Expand Global CDMO Footprint
|
On the 19th, Locus Cell announced the signing of a CDMO (Contract Development and Manufacturing Organization) agreement with CellFiber, a leading regenerative medicine company in Japan. Under the agreement, Locus Cell will support the production of clinical-grade products, with the total value estimated to exceed tens of millions of New Taiwan dollars. With the company’s fully automated GMP-compliant smart facility in Zhubei set to be completed by the end of the year, Locus Cell expects to seamlessly scale up to mass production and sees strong potential for expanding its CDMO business. |
| 2025-07-01 |
Comeback in Motion: EirGenix’s Licensing Partner Sandoz Resubmits EG12014 Biologics License Application to the FDA for Review
|
EirGenix announced on the 19th that its licensing partner, Sandoz, has resubmitted the Biologics License Application (BLA) for EG12014, a trastuzumab biosimilar lyophilized injection (150 mg), to the U.S. Food and Drug Administration (FDA) for review. |
| 2025-06-28 |
JUN ZHI Biomedical Partners with University of South Australia to Advance International Clinical Applications of Nano Mass Spectrometry
|
On the 18th, JUN ZHI Biomedical Co., Ltd. officially signed a Memorandum of Understanding (MOU) with the University of South Australia to jointly promote the clinical application and global expansion of its nano mass spectrometry diagnostic platform, bringing new momentum to the field of precision medicine worldwide. |
| 2025-06-28 |
Lotus Pharmaceutical to Acquire Five Drug Licenses in Vietnam for NT$457 Million, Accelerating ASEAN Expansion
|
On the 18th, Lotus Pharmaceutical announced that its subsidiary, Lotus International Pte. Ltd., has signed an asset purchase agreement with Vietnam’s Duy Tan Pharmaceutical Joint Stock Company. The deal involves acquiring trademarks, drug marketing approvals, and manufacturing supply agreements for five pharmaceutical products in Vietnam for a total consideration not exceeding USD 15.5 million (approximately NT$457 million). The transaction is expected to close in the third quarter. |
| 2025-06-28 |
PharmaEssentia’s New Drug Ropeg Approved in Argentina, Expanding Latin American Market After Brazil
|
PharmaEssentia announced on the 18th that its new drug Ropeginterferon alfa-2b (Ropeg) has received approval from Argentina’s National Administration of Drugs, Food and Medical Technology (ANMAT) for the treatment of polycythemia vera (PV). Following its approval in Brazil earlier this March, this marks another milestone for PharmaEssentia’s expansion into the Latin American market, further advancing its global business footprint. |
| 2025-06-28 |
Sunmax Biotechnology’s New Factory Passes QMS Certification, Bulk Solution Production Begins to Contribute, Revenue Growth Expected to Strengthen This Year
|
Sunmax Biotechnology, a collagen implant manufacturer, successfully passed its earnings distribution plan at its shareholders’ meeting yesterday (18th), approving a cash dividend of NT$11.6 per share. Chairman Barry Lin said after the meeting that although the economic outlook remains weak—especially in the medical aesthetics sector—the company’s uniquely positioned products remain in short supply. While the new factory is not expected to be fully operational until the first half of 2027 at the earliest, Sunmax obtained manufacturing approval under the medical device Quality Management System (QMS) guidelines at the end of April. This will allow the company to gradually start producing bulk solution for filling at the old plant, which will contribute incrementally to performance. Lin expects revenue growth momentum to strengthen somewhat this year, though a significant jump in performance will wait until the new factory’s full-scale production begins. |
| 2024-02-20 |
Taiwan's health ministry upgrades 3 hospitals to 'medical centers'
|
Taiwan News |
| 2024-02-05 |
Taiwan biomanufacturer aims to be ‘biotech TSMC’
|
Taipei Times |
